HMGA2 overexpression is the second major genetic alteration accounting for approximately 10% in uterine leiomyoma cases [194,195,196], but its expression is limited in the leiomyoma without underlying MED12 mutations [194,195,197,198,199]. This evidence concerns the gene MED12 and uterine corpus leiomyoma.